Skip to main content

Table 2 Details of pre- and study medication.

From: Improved functionality, health related quality of life and decreased burden of disease in patients with ADHD treated with OROS® MPH: is treatment response different between children and adolescents?

Age

6-12 years

N = 583

13-18 years

N = 239

All patients

N = 822

U-test2

Chi2-test3

Reason for starting OROS MPH, n (%)1

    

   N

142 (100.00)

82 (100.00)

224 (100.00)

p < 0.0903

   insufficient effectiveness

92 (64.79)

63 (76.83)

155 (69.20)

 

   adverse events

5 (3.52)

4 (4.88)

9 (4.02)

 

   combination of both

45 (31.69)

15 (18.29)

60 (26.79)

 

Dose of OROS MPH

    

   starting dose (mg/day)

29.05 ± 11.71

37.58 ± 15.62

31.53 ± 13.52

p < 0.0012

   minimum, median, maximum

18, 36, 72

18, 36, 108

18, 36, 108

 

   last visit

32.82 ± 12.68

41.95 ± 15.07

35.47 ± 14.04

p < 0.0012

   minimum, median, maximum

18, 36, 72

18, 36, 108

18, 36, 108

 

   Difference (mean ± SD)

3.77 ± 9.03

4.37 ± 10.43

3.94 ± 9.46

p = 0.5792

   Wilcoxon p-value

< 0.0001

< 0.0001

< 0.0001

 

Dose of OROS MPH (mg/day/kg BW)

N = 527 4

N = 223 4

N = 750 4

 

   starting dose (mg/day/kg BW)

0.90 ± 0.41

0.73 ± 0.39

0.85 ± 0.41

p < 0.0012

   minimum, median, maximum

0.30,0.82,3.13

0.20,0.66,2.77

0.20,0.78,3.13

 

   last visit

1.03 ± 0.45

0.82 ± 0.37

0.97 ± 0.44

p < 0.0012

   minimum, median, maximum

0.29,0.95,3.13

0.20,0.72,2.32

0.20,0.88,3.13

 

   Difference (mean ± SD)

0.13 ± 0.32

0.08 ± 0.20

0.11 ± 0.29

p = 0.6652

   Wilcoxon p-value

< 0.0001

< 0.0001

< 0.0001

 

Days of treatment with OROS MPH

82.90 ± 30.32

87.36 ± 27.15

84.20 ± 29.49

p = 0.0122

Days of observation

85.97 ± 29.35

89.05 ± 26.10

86.87 ± 28.46

p = 0.0462

Number (%) of patients with at least one additional application of IR MPH between study start and study end

    

   yes

180 (30.87)

68 (28.45)

248 (30.17)

p = 0.5463

   no

403 (69.13)

171 (71.55)

574 (69.83)

 
  1. 1 Data only available for patients (n = 224) from the GER-CON-2 study
  2. 2,3 p-values from the corresponding test between age groups: 6-12 years and 13-18 years
  3. 4 Determined only in patients with bodyweight documented at first and last visit
  4. Abbreviations: BW = bodyweight; IR = immediate-release; MPH = methylphenidate.